Sonia Quaratino

Dr. Sonia Quaratino has over twenty-five years of experience in research in immunology, clinical development at large pharmaceutical and biotechnology companies, has served on multiple boards, and overseen research programs at leading academic institutions. Most recently, Dr. Quaratino was Chief Medical Officer for Kymab, a biotech based in Cambridge with an innovative pipeline in immuno-oncology and immunology that was acquired by Sanofi in 2021. Dr. Quaratino has been Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics since May of 2020 and a non-executive director for TargoVax ASA since March of 2021. Previously, she held roles as Global Clinical Program Leader in Translational Clinical Oncology at Novartis in Basel and as Senior Medical Director and Immunology Advisor at Merck Serono in Darmstadt. At the University of Southampton, where she was Professor of Immunology, her research group focused on the interface between autoimmunity and cancer. Dr. Quaratino received her Medical Degree and Doctorate in Hematology-Oncology from the University of Palermo, and her Ph.D. in Immunology from Imperial College London.